Sun Pharma acquires Organon: growth engine or debt trap?

Subscribe to enjoy similar stories.With its $11.75 billion acquisition of Organon, a Merck spinoff, Sun Pharmaceutical has officially embarked on one of the most ambitious overseas expansions ever by an Indian pharmaceutical company. Markets cheered the announcement on 27 April, sending the stock soaring almost 7%.This reflects optimism around scale expansion and strategic repositioning.

With Organon’s $6.2 billion revenue and $1.9 billion Ebitda in CY25, the combined entity will hit a revenue of $12.4 billion, basis FY25 revenues for Sun Pharma. Ebitda stands for earnings before interest, taxes, depreciation, and amortization.For a company long seen primarily as a specialty generics exporter, this acquisition strengthens its pivot toward global branded and specialty therapies.

Organon brings three structural advantages – leadership in women’s health – an underpenetrated segment with strong pricing power; a robust biosimilars platform – exactly what the doctor ordered for pharma companies seeking higher-margin growth amid frequent pricing pressures in the competitive generics market; and geographic diversification across 18 large markets generating over $100 million each. The complementary footprint creates presence in all key regions, expanding Europe and adding China and Korea.The combined entity will become one of the top-3 global women’s health players, rank among the top-7 biosimilars companies, and lift the share of innovative medicines from 20% to 27%.But the risks – leverage, valuation, and execution – are worth noting.The transaction will be partly funded by bank financing to cover almost $8 billion of net debt on Organon’s books.